Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,819
archived clinical trials in
Brain Cancer

Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated:  11/28/2016
Children's Hospital of Philadelphia
416
mi
from 43215
Philadelphia, PA
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated: 11/28/2016
Children's Hospital of Philadelphia
416
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated:  11/28/2016
Children's Hospital of Pittsburgh of UPMC
165
mi
from 43215
Pittsburgh, PA
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated: 11/28/2016
Children's Hospital of Pittsburgh of UPMC
165
mi
from 43215
Pittsburgh, PA
Click here to add this to my saved trials
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated:  11/28/2016
Medical University of South Carolina
524
mi
from 43215
Charleston, SC
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated: 11/28/2016
Medical University of South Carolina
524
mi
from 43215
Charleston, SC
Click here to add this to my saved trials
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated:  11/28/2016
Palmetto Health Richland
422
mi
from 43215
Columbia, SC
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated: 11/28/2016
Palmetto Health Richland
422
mi
from 43215
Columbia, SC
Click here to add this to my saved trials
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated:  11/28/2016
BI-LO Charities Children's Cancer Center
355
mi
from 43215
Greenville, SC
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated: 11/28/2016
BI-LO Charities Children's Cancer Center
355
mi
from 43215
Greenville, SC
Click here to add this to my saved trials
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated:  11/28/2016
T C Thompson Children's Hospital
362
mi
from 43215
Chattanooga, TN
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated: 11/28/2016
T C Thompson Children's Hospital
362
mi
from 43215
Chattanooga, TN
Click here to add this to my saved trials
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated:  11/28/2016
East Tennessee Children's Hospital
275
mi
from 43215
Knoxville, TN
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated: 11/28/2016
East Tennessee Children's Hospital
275
mi
from 43215
Knoxville, TN
Click here to add this to my saved trials
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated:  11/28/2016
Vanderbilt-Ingram Cancer Center
334
mi
from 43215
Nashville, TN
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated: 11/28/2016
Vanderbilt-Ingram Cancer Center
334
mi
from 43215
Nashville, TN
Click here to add this to my saved trials
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated:  11/28/2016
University of Texas Southwestern Medical Center
910
mi
from 43215
Dallas, TX
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated: 11/28/2016
University of Texas Southwestern Medical Center
910
mi
from 43215
Dallas, TX
Click here to add this to my saved trials
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated:  11/28/2016
Cook Children's Medical Center
938
mi
from 43215
Fort Worth, TX
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated: 11/28/2016
Cook Children's Medical Center
938
mi
from 43215
Fort Worth, TX
Click here to add this to my saved trials
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated:  11/28/2016
Baylor College of Medicine
991
mi
from 43215
Houston, TX
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated: 11/28/2016
Baylor College of Medicine
991
mi
from 43215
Houston, TX
Click here to add this to my saved trials
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated:  11/28/2016
Methodist Children's Hospital of South Texas
1138
mi
from 43215
San Antonio, TX
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated: 11/28/2016
Methodist Children's Hospital of South Texas
1138
mi
from 43215
San Antonio, TX
Click here to add this to my saved trials
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated:  11/28/2016
University of Texas Health Science Center at San Antonio
1137
mi
from 43215
San Antonio, TX
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated: 11/28/2016
University of Texas Health Science Center at San Antonio
1137
mi
from 43215
San Antonio, TX
Click here to add this to my saved trials
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated:  11/28/2016
Naval Medical Center - Portsmouth
422
mi
from 43215
Portsmouth, VA
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated: 11/28/2016
Naval Medical Center - Portsmouth
422
mi
from 43215
Portsmouth, VA
Click here to add this to my saved trials
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated:  11/28/2016
Virginia Commonwealth University
344
mi
from 43215
Richmond, VA
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated: 11/28/2016
Virginia Commonwealth University
344
mi
from 43215
Richmond, VA
Click here to add this to my saved trials
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated:  11/28/2016
Seattle Children's Hospital
2005
mi
from 43215
Seattle, WA
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated: 11/28/2016
Seattle Children's Hospital
2005
mi
from 43215
Seattle, WA
Click here to add this to my saved trials
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated:  11/28/2016
Providence Sacred Heart Medical Center & Children's Hospital
1778
mi
from 43215
Spokane, WA
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated: 11/28/2016
Providence Sacred Heart Medical Center & Children's Hospital
1778
mi
from 43215
Spokane, WA
Click here to add this to my saved trials
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated:  11/28/2016
University of Wisconsin Hospital and Clinics
394
mi
from 43215
Madison, WI
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated: 11/28/2016
University of Wisconsin Hospital and Clinics
394
mi
from 43215
Madison, WI
Click here to add this to my saved trials
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated:  11/28/2016
Marshfield Clinic
488
mi
from 43215
Marshfield, WI
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated: 11/28/2016
Marshfield Clinic
488
mi
from 43215
Marshfield, WI
Click here to add this to my saved trials
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated:  11/28/2016
Princess Margaret Hospital for Children
11247
mi
from 43215
Perth,
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma
Status: Enrolling
Updated: 11/28/2016
Princess Margaret Hospital for Children
11247
mi
from 43215
Perth,
Click here to add this to my saved trials
FDOPA-PET/MRI for the Pre-operative Evaluation of Gliomas
FDOPA-PET/MRI for the Pre-operative Evaluation of Gliomas
Status: Enrolling
Updated:  11/29/2016
Washington University School of Medicine
397
mi
from 43215
St. Louis, MO
FDOPA-PET/MRI for the Pre-operative Evaluation of Gliomas
FDOPA-PET/MRI for the Pre-operative Evaluation of Gliomas
Status: Enrolling
Updated: 11/29/2016
Washington University School of Medicine
397
mi
from 43215
St. Louis, MO
Click here to add this to my saved trials
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  12/1/2016
Children's Hospital of Alabama
492
mi
from 43215
Birmingham, AL
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 12/1/2016
Children's Hospital of Alabama
492
mi
from 43215
Birmingham, AL
Click here to add this to my saved trials
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  12/1/2016
Providence Alaska Medical Center
3101
mi
from 43215
Anchorage, AK
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 12/1/2016
Providence Alaska Medical Center
3101
mi
from 43215
Anchorage, AK
Click here to add this to my saved trials
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  12/1/2016
Phoenix Children's Hospital
1658
mi
from 43215
Phoenix, AZ
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 12/1/2016
Phoenix Children's Hospital
1658
mi
from 43215
Phoenix, AZ
Click here to add this to my saved trials
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  12/1/2016
University of Arizona Medical Center University Campus
1639
mi
from 43215
Tucson, AZ
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 12/1/2016
University of Arizona Medical Center University Campus
1639
mi
from 43215
Tucson, AZ
Click here to add this to my saved trials
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  12/1/2016
Arkansas Children's Hospital
622
mi
from 43215
Little Rock, AR
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 12/1/2016
Arkansas Children's Hospital
622
mi
from 43215
Little Rock, AR
Click here to add this to my saved trials
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  12/1/2016
Southern California Permanente Medical Group
1973
mi
from 43215
Downey, CA
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 12/1/2016
Southern California Permanente Medical Group
1973
mi
from 43215
Downey, CA
Click here to add this to my saved trials
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  12/1/2016
City of Hope Comprehensive Cancer Center
1955
mi
from 43215
Duarte, CA
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 12/1/2016
City of Hope Comprehensive Cancer Center
1955
mi
from 43215
Duarte, CA
Click here to add this to my saved trials
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  12/1/2016
Loma Linda University Medical Center
1919
mi
from 43215
Loma Linda, CA
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 12/1/2016
Loma Linda University Medical Center
1919
mi
from 43215
Loma Linda, CA
Click here to add this to my saved trials
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  12/1/2016
Miller Children's and Women's Hospital Long Beach
1975
mi
from 43215
Long Beach, CA
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 12/1/2016
Miller Children's and Women's Hospital Long Beach
1975
mi
from 43215
Long Beach, CA
Click here to add this to my saved trials
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  12/1/2016
Childrens Hospital Los Angeles
1973
mi
from 43215
Los Angeles, CA
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 12/1/2016
Childrens Hospital Los Angeles
1973
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  12/1/2016
Children's Hospital Central California
1995
mi
from 43215
Madera, CA
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 12/1/2016
Children's Hospital Central California
1995
mi
from 43215
Madera, CA
Click here to add this to my saved trials
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  12/1/2016
Children's Hospital and Research Center Oakland
2098
mi
from 43215
Oakland, CA
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 12/1/2016
Children's Hospital and Research Center Oakland
2098
mi
from 43215
Oakland, CA
Click here to add this to my saved trials
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  12/1/2016
Children's Hospital of Orange County
1959
mi
from 43215
Orange, CA
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 12/1/2016
Children's Hospital of Orange County
1959
mi
from 43215
Orange, CA
Click here to add this to my saved trials
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  12/1/2016
Lucile Packard Children's Hospital Stanford University
2101
mi
from 43215
Palo Alto, CA
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 12/1/2016
Lucile Packard Children's Hospital Stanford University
2101
mi
from 43215
Palo Alto, CA
Click here to add this to my saved trials
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  12/1/2016
Sutter General Hospital
2043
mi
from 43215
Sacramento, CA
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 12/1/2016
Sutter General Hospital
2043
mi
from 43215
Sacramento, CA
Click here to add this to my saved trials
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  12/1/2016
University of California-Davis Comprehensive Cancer Ctr
2042
mi
from 43215
Sacramento, CA
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 12/1/2016
University of California-Davis Comprehensive Cancer Ctr
2042
mi
from 43215
Sacramento, CA
Click here to add this to my saved trials
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  12/1/2016
Rady Children's Hospital - San Diego
1948
mi
from 43215
San Diego, CA
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 12/1/2016
Rady Children's Hospital - San Diego
1948
mi
from 43215
San Diego, CA
Click here to add this to my saved trials
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  12/1/2016
UCSF Medical Center-Mission Bay
2105
mi
from 43215
San Francisco, CA
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 12/1/2016
UCSF Medical Center-Mission Bay
2105
mi
from 43215
San Francisco, CA
Click here to add this to my saved trials
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  12/1/2016
Children's Hospital Colorado
1153
mi
from 43215
Aurora, CO
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 12/1/2016
Children's Hospital Colorado
1153
mi
from 43215
Aurora, CO
Click here to add this to my saved trials
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  12/1/2016
Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
1162
mi
from 43215
Denver, CO
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 12/1/2016
Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
1162
mi
from 43215
Denver, CO
Click here to add this to my saved trials
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  12/1/2016
Connecticut Children's Medical Center
553
mi
from 43215
Hartford, CT
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 12/1/2016
Connecticut Children's Medical Center
553
mi
from 43215
Hartford, CT
Click here to add this to my saved trials
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  12/1/2016
Yale University
537
mi
from 43215
New Haven, CT
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 12/1/2016
Yale University
537
mi
from 43215
New Haven, CT
Click here to add this to my saved trials
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  12/1/2016
Alfred I. duPont Hospital for Children
396
mi
from 43215
Wilmington, DE
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 12/1/2016
Alfred I. duPont Hospital for Children
396
mi
from 43215
Wilmington, DE
Click here to add this to my saved trials
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  12/1/2016
Childrens National Medical Center
328
mi
from 43215
Washington,
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 12/1/2016
Childrens National Medical Center
328
mi
from 43215
Washington,
Click here to add this to my saved trials
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  12/1/2016
MedStar Georgetown University Hospital
328
mi
from 43215
Washington,
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 12/1/2016
MedStar Georgetown University Hospital
328
mi
from 43215
Washington,
Click here to add this to my saved trials
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  12/1/2016
Broward Health Medical Center
972
mi
from 43215
Fort Lauderdale, FL
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 12/1/2016
Broward Health Medical Center
972
mi
from 43215
Fort Lauderdale, FL
Click here to add this to my saved trials
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  12/1/2016
Golisano Children's Hospital of Southwest Florida
931
mi
from 43215
Fort Myers, FL
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 12/1/2016
Golisano Children's Hospital of Southwest Florida
931
mi
from 43215
Fort Myers, FL
Click here to add this to my saved trials
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  12/1/2016
University of Florida
714
mi
from 43215
Gainesville, FL
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 12/1/2016
University of Florida
714
mi
from 43215
Gainesville, FL
Click here to add this to my saved trials
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Status: Enrolling
Updated:  12/1/2016
Baptist Hospital of Miami
996
mi
from 43215
Miami, FL
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Status: Enrolling
Updated: 12/1/2016
Baptist Hospital of Miami
996
mi
from 43215
Miami, FL
Click here to add this to my saved trials